Evidence map›Paper›PMID 41220894›Full record

ArticleClinical kidney journal2025

Applicability of the Framingham Risk Score in predicting mortality among kidney failure patients: an international analysis.

Zhimin Chen, Xiejia Li, Abdul Rashid Qureshi, Rending Wang, Hong Jiang, Olof Heimbürger, Peter Barany, Jianghua Chen, Peter Stenvinkel, Bengt Lindholm

Abstract read
In one paragraph

Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhimin ChenKidney Disease Center, 1st Affiliated Hospital College of Medicine, Zhejiang University, Hangzhou, China.ORCID https://orcid.org/0000-0003-3942-9579
Xiejia LiRenal Medicine, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Abdul Rashid QureshiRenal Medicine, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0003-0536-5327
Rending WangKidney Disease Center, 1st Affiliated Hospital College of Medicine, Zhejiang University, Hangzhou, China.
Hong JiangKidney Disease Center, 1st Affiliated Hospital College of Medicine, Zhejiang University, Hangzhou, China.
Olof HeimbürgerRenal Medicine, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Peter BaranyRenal Medicine, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0001-6501-8293
Jianghua ChenKidney Disease Center, 1st Affiliated Hospital College of Medicine, Zhejiang University, Hangzhou, China.ORCID https://orcid.org/0000-0001-5958-8177
Peter StenvinkelRenal Medicine, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Bengt LindholmRenal Medicine, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The usefulness of the Framingham Risk Score (FRS) for estimation of mortality risk in kidney failure patients was explored in three cohorts of end-stage renal disease (ESRD) patients. Methods: Associations of the FRS with mortality risk were analysed among 392 Swedish non-dialysed (median age 56 years, males 62.8%, median FRS 19.5%) and 109 haemodialysed (median age 66 years, males 57.8%, median FRS 17.4%) ESRD patients and 1276 Chinese peritoneal dialysis (PD) patients (median age 50 years, males 55.6%, FRS 12.3%). We used Fine-Gray models to estimate relative risk associated with the FRS and its components, restricted mean survival time (RMST) to quantitate survival differences associated with the FRS and receiver operating characteristics curve analysis to estimate prognostic value of adding non-traditional risk factors to the FRS. Results: Despite different baseline characteristics, a 1 standard deviation increase in the FRS associated with similar increases (subhazard ratios 1.39-1.63) of both all-cause and cardiovascular mortality risk after adjusting for body mass index, serum albumin, haemoglobin and C-reactive protein (CRP). RMST and ∆RMST showed shorter survival time compared with all-cause and cardiovascular mortality in middle and high versus low FRS tertile. High versus low FRS tertiles showed 2- to 4-fold higher cumulative incident risk of all-cause and cardiovascular mortality. Adding non-traditional risk factors such as serum albumin and CRP to the FRS improved risk prediction marginally. Conclusions: A higher FRS associated with similar increases in mortality risk in three distinctly different cohorts of ESRD patients, whereas the addition of non-traditional risk factors had a negligible impact. The FRS is a valid tool for estimation of mortality risk in ESRD patients.

Indexed as

cardiovascular diseaseend-stage renal diseaseFramingham Risk Scoremortalitytraditional risk factors

Identifiers

PMID41220894
PMCPMC12598281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.